Healthcare | April 29, 2026
Sanofi Consumer Healthcare reports 33% revenue growth in Q1 FY26; PAT rises 36%
Domestic sales increased 15.5%, supported by the relaunch of previously recalled products in the market
Domestic sales increased 15.5%, supported by the relaunch of previously recalled products in the market
The Profit After Tax (PAT) for Q3 FY26 was Rs 49.68 crore, compared to Rs 46.78 crore in Q3 FY25
The company maintained a competitive ARPOB while steadily improving occupancy, driven by higher patient volumes and efficient capacity utilization
During the quarter, construction began on a US$ 10 million bioconjugation cGMP suite at NJ Bio’s Princeton site
Annual EBITDA margin expands by 170 basis points
Akums invested Rs. 272 crore in capital expenditure during FY25
Net Profit increased by 15% to Rs. 146 crores in Q4 FY25 and 19% to Rs. 660 crores in FY25
Profit after Taxes registered strong growth of 22% to Rs. 162 crores versus Rs. 134 crores in Q3 FY24
EBITDA margins expand to 31.3%
Stable profits, low leverage to keep credit profiles comfortable
Subscribe To Our Newsletter & Stay Updated
